Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004380 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
A Phase 1 study of Epithelial Ovarian Cancer, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT01004380 is a Phase 1 study of Epithelial Ovarian Cancer that has completed, run by Morphotek. The registered enrollment target is 15 participants, below the 211-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01004380, a Phase 1 study of Epithelial Ovarian Cancer, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
Conditions Studied
Interventions
- DRUG Farletuzumab, Carboplatin, and PLD
Study Locations (5)
Alabama
- University of Alabama at Birmingham Medical Center - Birmingham
Maryland
- Johns Hopkins University - Baltimore
New York
- Schwartz Gynecologic Oncology - Brightwaters
Tennessee
- Chattanooga GYN Oncology - Chattanooga
Texas
- International Beneficence Clinical Research, LLC - Harlingen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004380
The ClinicalTrials.gov registry entry for NCT01004380 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Farletuzumab, Carboplatin, and PLD is the first listed.
NCT01004380 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT01004380 about?
NCT01004380 is a clinical study titled "Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer". The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
What is the current status of trial NCT01004380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-11. Estimated completion is 2012-10.
What conditions does trial NCT01004380 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT01004380?
The interventions under investigation include: Farletuzumab, Carboplatin, and PLD (DRUG).
Who is sponsoring clinical trial NCT01004380?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01004380 being conducted?
This trial has 5 study locations across Alabama, Maryland, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
CT-95 in Advanced Cancers Associated With Mesothelin Expression
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.